Focus: Helsinn is a small-molecule biotech focused on oncology and gastroenterology, headquartered in Dublin with a diversified product portfolio anchored by VALCHLOR and AKYNZEO.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Helsinn to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Helsinn
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Helsinn's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Company's revenue anchor; small-molecule alkylating agent with 5-year patent cliff representing single-largest portfolio risk.
Second-largest revenue contributor; dual serotonin antagonist with extended exclusivity; includes IV formulation (fosnetupitant) in late-stage development.
Foundational serotonin antagonist nearing loss of exclusivity; active formulation line extensions in Phase 3 (oral, IV) may extend franchise lifecycle.
Niche FGFR inhibitor for biliary tract malignancies; Phase 1/2 expansion ongoing but limited near-term revenue contribution.
3 discontinued, 0 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo